You are here » Home » Companies » Company Overview » Suven Life Sciences Ltd

Suven Life Sciences Ltd.

BSE: 530239 Sector: Health care
NSE: SUVEN ISIN Code: INE495B01038
BSE 00:00 | 22 Jun 220.85 4.65
(2.15%)
OPEN

214.30

HIGH

222.00

LOW

209.80

NSE 00:00 | 22 Jun 221.20 4.85
(2.24%)
OPEN

214.95

HIGH

222.60

LOW

209.50

OPEN 214.30
PREVIOUS CLOSE 216.20
VOLUME 135687
52-Week high 250.80
52-Week low 155.00
P/E 17.74
Mkt Cap.(Rs cr) 2,811
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 214.30
CLOSE 216.20
VOLUME 135687
52-Week high 250.80
52-Week low 155.00
P/E 17.74
Mkt Cap.(Rs cr) 2,811
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Suven Life Sciences Ltd. (SUVEN) - Company History

Incorporated in Mar.'89 as a private limited company, Suven Pharmaceuticals (SPL) was converted into a public limited company in Jan.'95. It was promoted by Jasti Sudha Rani and Jasti Venkateswarlu, who is the present managing director. In Mar.'95, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the company's project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. The company manufactures bulk drugs and drug intermediates -- theophylline, caffeine, nitroso compound, cyanoacetic acid, etc. SPL has a sizeable export turnover through the export of drug intermediates to Germany, Switzerland, Israel, Europe, etc. During 1999-2000, the company has acquired a small pilot plant in Jeedimetla Industrial Estate,Hyderabad. During 2000-01, the company has registered a most remarkable record. The total sales of the company during 2000-01 has registered a growth of 71% over the previous year.The Profit After Tax(PAT) has also registered a growth of 325% over the previous year. The company has successfully achieved the re-certification of ISO 9002 during the year 2000-01. The company is planning to Modernize & Upgrade its R & D at Jeedimetla Industrial Estate.